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A B S T R A C T
Several countries oﬀer HPV self-sampling for screening non-attendees. It is assumed that screening attendees
also prefer self-sampling to clinician-based sampling, however, little research has been conducted with respect to
this. Women participating in the IMPROVE-study were randomised (1:1) to self- or clinician-collected HPV
testing, and HPV-positive women were retested using the other collection method. Three diﬀerent questionnaires
were sent out among a subset of participating women: Q1) HPV-positive women from both study groups were
asked about their experiences with self-sampling and clinician-based sampling (n=497); Q2) HPV-negative
women from the self-sampling group were asked about their experiences with self-sampling (n=2366); and Q3)
HPV-negative women in the clinician-collection group were asked about their experiences with clinician-based
sampling (n=2092). Response rates ranged from 71.6 to 79.4%. Women reported signiﬁcantly lower levels of
shame, nervousness, discomfort and pain during self-sampling compared to clinician-based sampling. However,
trust in correct sampling was signiﬁcantly higher during clinician-based sampling. The majority of women in
group Q1 preferred self-sampling (76.5%) to clinician-based sampling (11.9%) in future screening, while 11.6%
of women reported to have no preference for either method. To conclude, women from a regular screening
population have a positive attitude towards self-sampling but express some concerns with respect to accuracy.
The majority prefers self-sampling to clinician-based sampling in future screening. Based on these results, a
screening approach where women can choose for either self-sampling or clinician-based sampling seems highly
justiﬁable.
1. Introduction
Testing for the presence of high-risk human papillomavirus (HPV)
provides better protection against cervical cancer and high-grade cer-
vical intraepithelial neoplasia (CIN) than cytology testing (Arbyn et al.,
2012; Ronco et al., 2014). Therefore, several countries have replaced
cytology by HPV testing as the primary screening method (Wentzensen
et al., 2017). While cytology cannot be performed on a self-collected
cervicovaginal sample due to the lack of a suﬃcient number of intact
cervical cells (indicator cells), HPV testing can be performed reliably on
self-sampled specimen (HPV self-sampling) (Garcia et al., 2003). Hence,
the introduction of HPV-based screening opens up the possibility of
oﬀering self-sampling to women.
Studies have shown that oﬀering HPV self-sampling to screening
non-attendees increases participation rates (Virtanen et al., 2011a;
Virtanen et al., 2011b; Wikstrom et al., 2011; Giorgi Rossi et al., 2011;
Szarewski et al., 2011). Self-sampling participation rates up to 34.2%
were found among screening non-attendees in the Netherlands (Bais
et al., 2007; Gok et al., 2010; Gok et al., 2012; Bosgraaf et al., 2015;
Verhoef et al., 2014). Surveys evaluating women's experiences with
self-sampling, showed that most non-attendees would prefer self-sam-
pling to clinician-based sampling in the next screening round (Bosgraaf
et al., 2015; Huynh et al., 2010; Nelson et al., 2017). Besides, a meta-
analysis indicated that the sensitivity of HPV testing on self-collected
and clinician-collected specimens for detection of cervical in-
traepithelial grade 2 or worse (CIN2+) are similar when HPV testing is
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conducted with a clinically validated PCR-based assay (Arbyn et al.,
2014). Based on these results, several countries, including the Nether-
lands, have implemented HPV self-sampling for screening non-atten-
dees (Dutch Health Council, 2016; Lew et al., 2013; Danish Health
Council, 2017).
HPV self-sampling may also be considered as a primary screening
instrument in the screening population as a whole. Implementation of
self-sampling as a primary screening option would reduce the costs of
cervical screening as it obviates the need of smear taking at the phy-
sician's oﬃce The accuracy of HPV self-sampling as compared to HPV
testing on physician-collected specimens in women invited for routine
screening has recently been evaluated in the IMPROVE study (Polman
et al., 2019). The IMPROVE study, a randomised non-inferiority trial
among 16,410 women from a routine screening population in the
Netherlands, showed that HPV self-sampling has similar sensitivity and
speciﬁcity as clinician-based HPV testing for detection of CIN2+ and
CIN3+, further supporting the implementation of HPV self-sampling as
a primary screening option. It is generally hypothesized that screening
attendees, alike most non-attendees, would prefer self-sampling to
clinician-based sampling. However, little research has yet been con-
ducted with respect to experiences and preferences of regular screening
attendees.
The aim of this study was to evaluate experiences and preferences
with HPV self-sampling and clinician-based sampling among women
participating in routine screening. In order to evaluate this, we did a
survey among a subset of women who participated in the IMPROVE
study.
2. Methods
2.1. Study population
The IMPROVE study (Polman et al., 2019) was designed to assess
the non-inferiority of HPV self-sampling as compared to clinician-based
HPV testing. Women were invited to participate in the IMPROVE study
in 2015 and 2016. At that time, routine cervical screening in the
Netherlands was cytology-based and women aged 30–60 years were
invited every 5 years for sample collection for cervical cytology at a
general practitioner's practice. A total of 16,410 women provided in-
formed consent to participate. These women were randomised (1:1) to
the intervention group (HPV self-sampling using the Evalyn Brush,
Rovers Medical Devices B.V., Oss, The Netherlands) and the control
group (clinician-based HPV testing using the Cervex Brush, Rovers
Medical Devices B.V., Oss, The Netherlands). Both self-sampling and
clinician-based sampling were oﬀered free of charge, as is participation
in routine screening in the Netherlands. Both within the IMPROVE
study and within routine screening, women were informed that possible
additional research in case of a positive screening test result could
entail costs. The IMPROVE study was approved by the Ministry of
Public Health (no. 2014/32) and is registered in the Dutch Trial Reg-
ister (NTR5078).
To assess the relative sensitivity of self-collected compared to clin-
ician-based HPV testing in the IMPROVE study, HPV-positive women in
the intervention group were also tested for HPV on a clinician-collected
sample, and HPV-positive women in the control group were requested
to send in a self-sample for HPV testing. This second test (i.e. cross-test)
was also free of charge.
For this survey, three diﬀerent questionnaires were developed (see
Fig. 1): questionnaire 1 (Q1): HPV-positive women from both study
groups were asked about their experiences with both self-sampling and
clinician-based sampling; questionnaire 2 (Q2): HPV-negative women
from the intervention group were asked about their experiences with
self-sampling; and questionnaire 3 (Q3): HPV-negative women from the
control group were asked about their experiences with clinician-based
sampling.
Invitations to participate in the questionnaire study were sent out in
January 2017. Because of privacy and ethical reasons, questionnaires
were completely anonymous and therefore could not be linked to the
IMPROVE study on the individual level. To minimize the risk of recall
bias, women who tested HPV positive between June and November
2016 (n=497 HPV-positive women [Q1]) and women who tested HPV
negative between September and November 2016 (n=4458; 2366
women in the intervention group [Q2] and 2092 in the control group
[Q3])were invited to participate.
2.2. Questionnaire
The questionnaires (see supplementary material) were developed
based on previous studies evaluating experiences with HPV self-sam-
pling (Bosgraaf et al., 2015; Sultana et al., 2015; Virtanen et al., 2014;
Karjalainen et al., 2016; Berner et al., 2013; Waller et al., 2006). The
questionnaires were tested in an external pilot group of ten women
within the screening age in order to make sure that the questions were
clear and understandable.
The questionnaires contained three to ﬁve components. The ﬁrst
component contained questions about age, level of education and
screening history and was included in Q1, Q2, and Q3. The second
component contained questions about the intelligibility of the given
instructions and the usability of the self-sampling device and was in-
cluded in Q1 and Q2. The third component contained questions about
experiences with self-sampling and/or clinician-based sampling (dis-
comfort, pain, nervousness, shame, privacy and trust in correct execu-
tion of the sampling procedure) and was included in Q1, Q2 and Q3. In
addition, Q2 and Q3 had one extra question regarding trust in accuracy
of the HPV result. HPV-positive women in the IMPROVE study were
advised to undergo follow-up testing and had often already received
additional test results, making this question unsuitable for HPV-posi-
tives. The fourth component contained questions about preference for
participation in future screening (self-sampling, clinician-based sam-
pling, or no preference) and was included in Q1 and Q2. The ﬁfth
component contained questions about knowledge with respect to HPV
and cervical cancer, feelings of concern after receiving the HPV-positive
test result, and whether the provided information after receiving the
HPV-positive test result was reassuring. Since we aimed to evaluate
what information HPV-positive women wanted to receive and how they
could best be reassured after receiving the test result, this part of the
questionnaire was only included in Q1. Women could either ﬁll in the
questionnaire on paper and sent it back using the provided return en-
velope, or log in and ﬁll in the questionnaire online. Formatted re-
sponses were either binary (yes/no) or on a ﬁve point Likert-type scale.
2.3. Statistical analysis
Diﬀerences in age between women who participated in Q2 versus
Q3 were analysed with the Mann-Whitney U test, while diﬀerences in
level of education and time to previous cervical smear were analysed
with the Chi-square test.
Scores were ﬁlled in on a ﬁve-point scale and are presented with
mean and median scores. Diﬀerences in scores between self-sampling
and clinician-based sampling among HPV-positive women (Q1) were
analysed using the Wilcoxon Signed-Rank test, while diﬀerences in
scores between HPV-negative women from the self-sampling and clin-
ician-based sampling group (Q2 vs. Q3) were analysed using the Chi-
square test. The presented p-values are Bonferroni corrected (multiplied
by the number of hypotheses tested, i.e. multiplied by 13).
Preference in future screening was only analysed for women who
had experience with both self-sampling and clinician-based sampling
and therefore were able to make an informed decision regarding their
preference for the next screening round. Therefore, only HPV-positive
women (Q1) and HPV-negative women from the intervention group
(Q2) who indicated that they had participated in cervical screening
before were included in this analysis. The eﬀect of age on preference in
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future screening was evaluated with the Kruskal Wallis test, while dif-
ferences between lower and higher educated women on preference in
future screening were evaluated with the Chi-square test. As there was a
small percentage of missing data, these were excluded for analysis. Data
analysis was performed with IBM SPSS Statistics version 22.0.
3. Results
3.1. Response rate and study cohort characteristics
Response rates of the Q1, Q2, and Q3 group ranged from 71.6% to
79.4% (see Fig. 1). Overall, 68.0% of women (n=2608) completed the
questionnaire on paper and 32.0% (n=1227) completed the ques-
tionnaire online. Demographic characteristics of the questionnaire re-
sponders are shown in Table 1. There were no diﬀerences with respect
to age, educational level, and time to previous cervical smear between
women ﬁlling out Q2 and Q3 (p=0.886, p=0.916, and p=0.083,
respectively).
3.2. Self-sampling instructions and usability
Results regarding intelligibility of the self-sampling instructions and
usability of the self-sampling device, both for HPV-positive women in
the Q1 group and HPV-negative women in the self-sampling group Q2,
are shown in Table 2. Overall, > 95% of women reported a very to
extremely good intelligibility of the self-sampling instructions (95.5%
in Q1 and 96.5% in Q3). Moreover, 77.7% of women in Q1 group and
84.6% of women in Q3 group reported a very to extremely good us-
ability of the self-sampling device.
3.3. Experience of self-sampling versus clinician-based sampling
Results among HPV-positive women (Q1) who performed both self-
sampling and clinician-based sampling are shown in Table 3. Women
reported signiﬁcantly less discomfort during self-sampling as compared
to clinician-based sampling: 68.7% reported no discomfort at all during
self-sampling, compared to 19.2% during clinician-based sampling
(p=0.002). Additionally, 80.8% of women reported no pain at all
during self-sampling, compared to 33.0% of women during clinician-
based sampling (p < 0.001). Women reported signiﬁcantly lower le-
vels of nervousness and shame during self-sampling than during clin-
ician-based sampling: 62.0% vs. 27.6% reported no nervousness at all
(p=0.018) and 92.1% vs. 37.3% reported no shame at all
(p < 0.001). The vast majority of women experienced a high degree of
privacy during self-sampling (93.2%), while only 31.4% reported this
during clinician-based sampling (p < 0.001). Finally, 53.7% of women
reported maximal trust in correct execution of the self-sampling pro-
cedure, compared to 73.3% that reported extreme trust in correct ex-
ecution of the clinician-based sampling procedure (p < 0.001).
Results of HPV-negative women from the self-sampling group versus
HPV-negative women from the clinician-based sampling group (Q2 vs.
Q3) are shown in Table 4. The majority (76.9%) of women from the
self-sampling group reported no discomfort at all while performing self-
sampling, while only 28.3% of women from the control group reported
no discomfort during clinician-based sampling (p < 0.001). Moreover,
81.9% of women in the self-sampling group reported no pain, compared
to 40.1% of women in the clinician-based sampling group (p < 0.001).
Women from the self-sampling group reported signiﬁcantly lower levels
of nervousness and shame as compared to women from the clinician-
based sampling group: 63.7% vs. 43.0% reported no nervousness at all
(p < 0.001) and 91.4% vs. 47.9% reported no shame at all
(p < 0.001). With regard to privacy, 95.5% of women in the self-
sampling group reported extremely high privacy compared to 61.8% of
women in the clinician-based sampling group (p < 0.001). The per-
centage of women who reported extreme trust in correct execution of
the sampling procedure was 53.3% in the self-sampling group and
Intervention group
Self-sampling
Control group
Clinician-based sampling
HPV-positive
Cross HPV-testing*
Questionnaire 1
Questionnaires sent out
n = 497 
HPV-negativeHPV-negative
Questionnaire 2
Questionnaires sent out 
n = 2,366
Questionnaire 3
Questionnaires sent out 
n = 2,092
Responses
n = 1,878 (79.4%)
Responses
n = 356 (71.6%)
Responses
n = 1,601 (76.5%)
IMPROVE study
Questionnaire study
Fig. 1. Flowchart of the IMPROVE study design, including information on participation in the questionnaire study.
* Cross-testing: HPV-positive women in the intervention group were also tested for HPV on a clinician-collected sample, and HPV-positive women in the control
group were also tested for HPV on a self-sample.
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64.4% in the clinician-based sampling group (p < 0.001). Finally,
54.1% of women in the self-sampling group reported extreme trust
towards the test result, as compared to 59.4% of women in the clin-
ician-based sampling group (p=0.002).
3.4. Preference in future screening
Among 356 HPV-positive women who participated in both self-
sampling and clinician-based sampling within the IMPROVE trial (Q1),
353 ﬁlled in the question about a preference for future screening. The
vast majority of these women (76.5%) reported to prefer self-sampling
in future screening, 11.9% reported to prefer clinician-based sampling
and 11.6% reported to have no preference for either method. The
preferred screening method in future screening was not inﬂuenced by
age, level of education, or screening history (p=0.502, p=0.811, and
p=0.550, respectively).
A total of 1674 (89.1%) of 1878 HPV-negative women in the self-
sampling group (Q2) reported that they had previously participated in
screening. Of these, 1662 ﬁlled in the question about preference in
future screening. The vast majority of these women (89.4%; n=1486)
reported to prefer self-sampling to clinician-based sampling in future
screening. In contrast, 2.8% (n=47) of women reported to prefer
clinician-based sampling for future screening and 7.8% (n=129) of
women reported that they had no preference for either method. The
preferred screening method in future screening was not inﬂuenced by
age, level of education, or screening history (p=0.894, p=0.086, and
p=0.434, respectively). When we analysed preference for future
screening among all HPV-negative women (Q2 and Q3), irrespective of
whether they have experience with both sampling methods, 2420
(70.1%) reported to prefer self-sampling to clinician-based sampling in
future screening, while 439 (12.7%) reported to prefer clinician-based
sampling and 595 (17.2%) reported to have no preference.
3.5. Knowledge and attitudes
A total of 157 (44.5%) of 353 HPV-positive women reported to be
fully familiar with the relation between HPV and cervical (pre)cancer.
However, also a substantial proportion of women (28.3%, 100 of 353)
reported not to be familiar at all with this causal relationship (mean
score: 3.4). Among HPV-positive women, 17.0% (60 of 353) reported
not to be concerned or only slightly concerned, after being informed
about the HPV-positive test result, while 51.8% of women reported to
be very or extremely concerned. Most women (49.7%; 175 of 352)
reported that the information provided in the result letter, via the
website and/or via the information line was very to extremely re-
assuring, while 15.9% (56 of 352) reported that the provided
Table 1
Demographic characteristics of responders to questionnaire 1 (HPV-positive women from both study groups), questionnaire 2 (HPV-negative women from the
intervention group), and questionnaire 3 (HPV-negative women from the control group).
Questionnaire 1 Questionnaire 2 Questionnaire 3
Characteristics n % n % n %
Mean age in years (range) 43.7 (30–60) 48.4 (30–63) 48.4 (30–61)
Age cohorts
30–33 74 20.9% 105 5.6% 82 5.1%
34–38 46 13.0% 129 6.9% 130 8.1%
39–43 35 9.9% 246 13.2% 207 13.0%
44–48 51 14.4% 361 19.3% 266 16.7%
49–53 67 18.9% 316 16.9% 295 18.5%
54–58 53 15.0% 376 20.1% 344 21.5%
59–63 28 7.9% 337 18.0% 273 17.1%
Missing 2 – 8 – 4 –
Level of education
No or primary education 1 0.3% 13 0.7% 12 0.8%
Secondary education 48 13.6% 396 21.1% 321 20.2%
Intermediate/Higher vocational education 212 59.9% 1116 59.6% 951 59.7%
University 93 26.3% 348 18.6% 309 19.4%
Missing 2 – 5 – 8 –
Time to previous cervical smear
Women aged< 34 years (ﬁrst invitation for cervical screening) 74 21.1% 104 5.6% 82 5.2%
Women aged ≥34 years
< 7 years 243 69.2% 1545 83.7% 1353 86.6%
7–12 years 16 4.6% 107 5.8% 79 5.1%
≥13 years ago 6 1.7% 22 1.2% 11 0.7%
Never 12 3.4% 68 3.7% 38 2.4%
Missing 5 – 32 – 38 –
Total 356 1878 1601
Table 2
Experiences regarding instructions and intelligibility of self-sampling in HPV-positive women (questionnaire 1) and HPV-negative women from the intervention
group (questionnaire 2).
1- not at all 2-slightly 3-moderately 4-very 5-extremely Total Missing
Mean (95% CI) Median (Range) n % n % n % n % n % n n
Intelligibility of self-sampling instructions
Questionnaire 1 4.7 (4.61–4.73) 5 (2–5) 0 0.0% 2 0.6% 14 3.9% 83 23.3% 257 72.2% 356 0
Questionnaire 2 4.7 (4.67–4.72) 5 (1–5) 4 0.2% 14 0.7% 47 2.5% 413 22.0% 1397 74.5% 1875 3
Usability of self-sampling device
Questionnaire 1 3.1 (2.99–3.27) 5 (1–5) 28 7.9% 38 10.7% 13 3.7% 55 15.5% 220 62.1% 354 2
Questionnaire 2 3.4 (3.32–3.42) 5 (1–5) 92 4.9% 131 7.0% 66 3.5% 287 15.3% 1296 69.2% 1872 6
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information was not or only slightly reassuring.
4. Discussion
We aimed to evaluate experiences with HPV self-sampling as com-
pared to clinician-based sampling among women from a routine Dutch
screening cohort. Overall, results show that experiences with self-
sampling were rated more positive than experiences with clinician-
based sampling. Intelligibility of the self-sampling instructions was
rated good and usability of the self-sampling device was rated moder-
ately good. Women experienced signiﬁcantly lower levels of
discomfort, pain, nervousness and shame with self-sampling, and sig-
niﬁcantly higher levels of privacy. Trust in correct execution of sam-
pling method and trust in accuracy of the HPV result were slightly
lower with self-sampling as compared to clinician-based sampling.
Nonetheless, the majority of women reported to prefer self-sampling in
future screening.
Previous studies among non-attendees who were oﬀered self-sam-
pling showed that women found self-sampling to be more convenient,
less embarrassing, less uncomfortable and less painful as compared to
clinician-based sampling (Sultana et al., 2015). In addition, women
indicated that they would prefer self-sampling to clinician-based
Table 3
Experiences with self-sampling and clinician-based sampling (Q1).
1-not at all 2-slightly 3-moderately 4-very 5-extremely Total Missing
Mean (95% CI) Median (Range) P-value⁎ n % n % n % n % n % n n
Discomfort
Self-sampling 1.4 (1.35–1.49) 1 (1–5) < 0.001 244 68.7% 84 23.7% 19 5.4% 6 1.7% 2 0.6% 355 1
Clinician-based sampling 2.8 (2.70–2.96) 3 (1–5) 68 19.2% 71 20.0% 103 29.0% 80 22.5% 33 9.3% 355 1
Pain
Self-sampling 1.3 (1.22–1.36) 1 (1–5) < 0.001 286 80.8% 45 12.7% 14 4.0% 6 1.7% 3 0.8% 354 2
Clinician-based sampling 2.4 (2.25–2.51) 2 (1–5) 116 33.0% 86 24.4% 72 20.5% 57 16.2% 21 6.0% 352 4
Nervousness
Self-sampling 1.6 (1.46–1.64) 1 (1–5) < 0.001 220 62.0% 95 26.8% 24 6.8% 13 3.7% 3 0.8% 355 1
Clinician-based sampling 2.6 (2.50–2.77) 3 (1–5) 98 27.6% 68 19.2% 84 23.7% 73 20.6% 32 9.0% 355 1
Shame
Self-sampling 1.1 (1.05–1.13) 1 (1–4) < 0.001 327 92.1% 24 6.8% 3 0.8% 1 0.3% 0 0.0% 355 1
Clinician-based sampling 2.2 (2.09–2.35) 2 (1–5) 132 37.3% 88 24.9% 76 21.5% 41 11.6% 17 4.8% 354 2
Privacy
Self-sampling 4.8 (4.71–4.89) 5 (1–5) < 0.001 15 4.2% 1 0.3% 1 0.3% 7 2.0% 329 93.2% 353 3
Clinician-based sampling 3.6 (3.44–3.71) 4 (1–5) 31 8.8% 50 14.1% 65 18.4% 97 27.4% 111 31.4% 354 2
Trust in correct execution of sampling procedure
Self-sampling 4.3 (4.25–4.43) 5 (1–5) < 0.001 6 1.7% 12 3.4% 28 7.9% 119 33.4% 191 53.7% 356 0
Clinician-based sampling 4.7 (4.61–4.73) 5 (1–5) 1 0.3% 3 0.8% 13 3.7% 78 21.9% 261 73.3% 356 0
⁎ Bonferroni corrected p-value.
Table 4
Experiences with self-sampling in the intervention group (Q2) versus experiences with clinician-based sampling in the control group (Q3).
1-not at all 2-slightly 3-moderately 4-very 5-extremely Total Missing
Mean (95% CI) Median (Range) P-value⁎ n % n % n % n % n % n n
Discomfort
Self-sampling 1.3 (1.31–1.37) 1 (1–5) < 0.001 1441 76.9% 285 15.2% 96 5.1% 42 2.2% 10 0.5% 1874 4
Clinician-based
sampling
2.4 (2.34–2.46) 2 (1–5) 451 28.3% 474 29.7% 355 22.3% 218 13.7% 97 6.1% 1595 6
Pain
Self-sampling 1.3 (1.25–1.59) 1 (1–5) < 0.001 1534 81.9% 224 12.0% 58 3.1% 44 2.3% 13 0.7% 1873 5
Clinician-based
sampling
2.1 (2.08–2.20) 2 (1–5) 639 40.1% 427 26.8% 264 16.6% 190 11.9% 75 4.7% 1595 6
Nervousness
Self-sampling 1.6 (1.52–1.61) 1 (1–5) < 0.001 1194 63.7% 401 21.4% 182 9.7% 80 4.3% 16 0.9% 1873 5
Clinician-based
sampling
2.1 (2.00–2.10) 2 (1–5) 687 43.0% 403 25.2% 304 19.0% 154 9.6% 49 3.1% 1597 4
Shame
Self-sampling 1.1 (1.09–1.13) 1 (1–5) < 0.001 1712 91.4% 126 6.7% 23 1.2% 6 0.3% 6 0.3% 1873 5
Clinician-based
sampling
1.9 (1.87–1.97) 2 (1–5) 764 47.9% 414 26.0% 233 14.6% 145 9.1% 39 2.4% 1595 6
Privacy
Self-sampling 4.9 (4.84–4.90) 5 (1–5) < 0.001 51 2.7% 3 0.2% 7 0.4% 24 1.3% 1788 95.5% 1873 5
Clinician-based
sampling
4.3 (4.29–4.39) 5 (1–5) 67 4.2% 58 3.6% 130 8.1% 354 22.2% 987 61.8% 1596 5
Trust in correct execution of sampling procedure
Self-sampling 4.4 (4.33–4.41) 5 (1–5) < 0.001 7 0.4% 42 2.2% 194 10.4% 631 33.7% 998 53.3% 1872 6
Clinician-based
sampling
4.5 (4.48–4.56) 5 (1–5) 13 0.8% 29 1.8% 107 6.7% 420 26.3% 1030 64.4% 1599 2
Trust in test result
Self-sampling 4.4 (4.41–4.47) 5 (1–5) 0.005 4 0.2% 11 0.6% 157 8.4% 687 36.7% 1011 54.1% 1870 8
Clinician-based
sampling
4.5 (4.47–4.53) 5 (1–5) 10 0.6% 12 0.8% 88 5.5% 538 33.7% 947 59.4% 1595 6
⁎ Bonferroni corrected p-value.
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sampling for future screening (Bosgraaf et al., 2015; Sultana et al.,
2015; Virtanen et al., 2014; Karjalainen et al., 2016). Results of the
current study are in line with previous studies and show that experi-
ences and preferences regarding self-sampling do also apply to a routine
screening population. Previous studies that evaluated self-sampling
experiences in a routine screening population showed, as in the current
study, that women reported self-sampling to be convenient and user-
friendly (Waller et al., 2006; Ketelaars et al., 2017). Moreover, 63% of
women reported to prefer self-sampling over clinician-based sampling
for future screening, as compared to about 80% in the current study
(Ketelaars et al., 2017).
As in several previous studies (Sultana et al., 2015; Waller et al.,
2006), women in the current study performing self-sampling reported
signiﬁcantly lower levels of trust in correct execution of the sampling
procedure and in the test result as compared to clinician-based sam-
pling. Trust in correct execution of sampling procedure and in the test
result are likely to increase when additional evidence about the clinical
accuracy of HPV self-sampling in a routine screening population be-
comes available to women. In this regard, the results of the IMPROVE
study, showing that HPV self-sampling is non-inferior to clinician-based
HPV testing with respect to detection of CIN2+ and CIN3+, are en-
couraging and may help to reduce uncertainties about HPV self-sam-
pling. If women become informed that self-sampling is a reliable and
safe method for participation in cervical screening, it is to be expected
that an even higher proportion of women would prefer self-sampling.
Here, the authorities responsible for screening programs, as well as
general practitioners, physician assistants and gynaecologists, play an
important role in informing and educating women, and are likely to
have major impact on the acceptability of HPV self-sampling.
A majority of HPV-negative women (89%) indicated to prefer self-
sampling to clinician-based sampling in future screening. HPV-positives
also reported a preference towards self-sampling, however, slightly less
pronounced: 77% preferred self-sampling. A possible explanation for
the diﬀerence in preference between HPV-negative and HPV-positive
women is that self-sampling HPV-positives in the IMPROVE study still
had to undergo clinician-based sampling for cytology triage (Polman
et al., 2019). This second step may be experienced as burdensome and
may have decreased HPV-positive women's preference regarding self-
sampling as compared to HPV-negative women. Direct triage tests for
HPV-positive samples that are applicable on self-collected samples may
overcome this problem. Cytology testing cannot be accurately per-
formed on self-collected samples, but molecular triage testing may
provide a solution in the future (Luttmer et al., 2016; Ebisch et al.,
2016; Verlaat et al., 2018; Snoek et al., 2019).
In this study, all women performing self-sampling used the Evalyn
brush. Consequently, results with regard to usability, discomfort, pain,
nervousness, shame, privacy, trust in correct execution of sampling
procedure, and trust in accuracy of the HPV result were reported spe-
ciﬁcally for this brush-based self-sampling device. However, previous
studies reported similar acceptability and experiences between brush-
and lavage-based self-sampling devices (Bosgraaf et al., 2015;
Karjalainen et al., 2016)
Important strengths of this study are its large sample size and its
setting within the nationwide screening programme in the Netherlands.
However, there are also some limitations. The IMPROVE study was an
opt-in study with a fairly low response rate: only 16,000 out of 185,000
invited women participated in the IMPROVE study. Moreover, among
participating women, there was a higher percentage of withdrawal
among women randomised to clinician-based sampling as compared to
self-sampling, which may indicate a pre-existing preference for self-
sampling among study participants. This may raise questions about the
representativeness of the IMPROVE study for a routine screening set-
ting. However, women in the IMPROVE cohort had a similar screening
history and CIN2+ rate as women participating in the national
screening programme, indicating that the IMPROVE study population
does not represent a subset of underscreened women. The IMPROVE
population may still be a cohort in which the attitude towards HPV self-
sampling is more positive than in the routine screening population,
although results observed in our study are consistent with other pre-
ference studies. Another limitation of this study is that women received
the questionnaire a few months after participation in the IMPROVE
trial. Therefore, results may be subject to recall bias. However, in order
to minimize this type of bias, questionnaires were only sent to women
who had participated in the IMPROVE study within six months prior to
the start of the questionnaire study. Another limitation is that, because
of privacy and ethical regulations in the Netherlands, questionnaires
were completely anonymous and therefore could not be linked to the
IMPROVE study on the individual level.
Future research should focus on the clinical accuracy of other self-
sampling devices in combination with HPV assays, and on the experi-
ences and preferences of women, and the participation rate of self-
sampling as a primary screening method in routine screening.
Depending on results of these studies self-sampling might be oﬀered as
a primary method in the future. Arguments that are expected to play a
role in the discussion about how to screen women in the future are cost-
eﬀectiveness, maximisation of screening coverage, and women their
preferences.
In conclusion, results of this study show that women from a routine
screening population have a positive attitude towards self-sampling but
do express some concerns with respect to accuracy. Moreover, the
majority of these women prefer self-sampling to clinician-based sam-
pling in future screening. These results are supportive of self-sampling
as a female-friendly primary screening method. Given that there are
some concerns about the reliability of self-sampling and a minority of
women prefer clinician-based sampling, a screening approach where
women can choose for either method seems highly justiﬁable.
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